Expert: Selective inhibitor of URAT1 (urate transporter 1) in the proximal tubule of the kidney. URAT1 mediates ~90% of uric acid reabsorption from the tubular lumen. Inhibition increases renal uric acid excretion, lowering serum uric acid (sUA). Next-generation design aims for improved selectivity and potency over lesinurad/probenecid with reduced renal toxicity.

Everyday: Blocks the kidney's uric acid "recycling door" (URAT1 transporter). Normally, kidneys filter uric acid out but then reabsorb most of it back. This drug jams that reabsorption door shut, so more uric acid gets flushed out in urine. Like fixing a plumbing problem — the drain was working fine, the problem was the pipe that kept pulling the waste back.

Targets: []

Primary EP: [{"id":"red2-ep1","name":"sUA <6 mg/dL at Month 6","type":"PRIMARY","unit":"%","results":[],"timepoint":"Month 6","description":"Proportion achieving serum uric acid below 6 mg/dL at 6 months. Longer

Primary EP: [{"id":"red1-ep1","name":"sUA <6 mg/dL at Month 6","type":"PRIMARY","unit":"%","results":[],"timepoint":"Month 6","description":"Same primary endpoint as REDUCE-2. Replication needed for regulatory fi

Primary EP: [{"id":"pozd2b-ep1","name":"sUA <6 mg/dL at 12 weeks","type":"PRIMARY","unit":"%","results":[{"arm":"pozd-75","label":"89% (75 mg)","value":89},{"arm":"pozd-50","label":"78% (50 mg)","value":78},{"arm

Safety: No serious adverse events in pozdeutinurad-treated patients. Most common AEs (mild-moderate): diarrhea, headache, upper respiratory infection. No elevation of serum creatinine (key differentiator vs l

Pozdeutinurad - Progressive Gout - Ph3 - Topline (REDUCE-2) Q2 2026

Pozdeutinurad - Progressive Gout - Ph3 - Topline (REDUCE-1) Q4 2026

Next-gen oral URAT1 inhibitor for progressive and tophaceous gout. Acquired via Arthrosi Therapeutics (completed Feb 9, 2026). Two Phase 3 trials: REDUCE 1 (n=750, data Q2 2026) and REDUCE 2 (data Q4 2026). 3 arms: 50mg, 75mg, placebo. Primary endpoint: sUA reduction by month 6, secondary endpoints include tophi resolution and flare reduction. If successful, addresses much larger population than NASP — gout patients who are inadequate responders to standard oral ULT. Potential complement to NASP in building SOBI gout franchise.